Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T18:12:41.530Z.
Calculation as of: 2026-10-06T18:12:41.530Z.
Quote observation: 2026-10-06T18:10:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76fc2c3b696fe1037033af5d10d354cd3b8573abd6cfebee9ff2ae185940ee40
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$2.44B
Free Cash Flow Yield
0.77%
TTM Avg
2.55%
3Y Avg
5.86%
5Y Avg
6.02%
Market Cap
$2.40B
Free Cash Flow Yield
3.09%
TTM Avg
2.66%
3Y Avg
2.65%
5Y Avg
2.78%
Market Cap
$2.38B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.37B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.36B
Free Cash Flow Yield
4.94%
TTM Avg
2.84%
3Y Avg
1.97%
5Y Avg
1.97%
Market Cap
$2.34B
Free Cash Flow Yield
2.59%
TTM Avg
0.99%
3Y Avg
0.99%
5Y Avg
0.99%
Market Cap
$2.33B
Free Cash Flow Yield
N/A
TTM Avg
2.55%
3Y Avg
2.55%
5Y Avg
2.55%
Market Cap
$2.33B
Free Cash Flow Yield
2.64%
TTM Avg
4.21%
3Y Avg
3.09%
5Y Avg
2.61%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Disc Medicine, Inc. (IRON) | $2.42B | N/A | N/A | N/A | N/A |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.44B | 0.77% | 2.55% | 5.86% | 6.02% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | 3.09% | 2.66% | 2.65% | 2.78% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.38B | N/A | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.37B | N/A | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 4.94% | 2.84% | 1.97% | 1.97% |
| Liquidia Corporation (LQDA)vs › | $2.34B | 2.59% | 0.99% | 0.99% | 0.99% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.33B | N/A | 2.55% | 2.55% | 2.55% |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 2.64% | 4.21% | 3.09% | 2.61% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.52B | N/A | 12.15% | 12.15% | 12.15% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
